IDH1 and glioblastoma: In this study, we employed multi-modal molecular and clinical analyses of diverse, independent patient datasets (TCGA, IvyGap, CPTAC, and single-cell transcriptomics) to develop a new classification system for IDH wild-type GBM patients.